The biosimilar pharmaceutical filgrastims, a less expensive version of the biologic pharmaceutical filgrastim, is the first global oncology biosimilar product. Unlike small-molecule generic drugs, biosimilar filgrastim was approved by regulatory agencies following review of clinical, toxicology, pharmacokinetic, and pharmacodynamic data. Adoption of biosimilar filgrastim can decrease health care costs and improve access to filgrastim products.1 In the European Union, 8 biosimilar filgrastim products account for 60% of filgrastim usage.2 In Japan, 3 biosimilar filgrastims account for 46% of filgrastim usage. In the United States, a single biosimilar filgrastim accounts for 15% to 26% usage.3
Qureshi ZP, Nagai S, Bennett CL. Biosimilar Filgrastim Use in the United States vs the European Union and Japan—Why Does It Lag Behind and What Can Be Done? JAMA Oncol. Published online December 03, 20185(3):297–298. doi:10.1001/jamaoncol.2018.5636
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: